Compare Mesoblast Limited (MESO) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Realty Income Corp — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Realty Income Corp trades at $54.2 (market cap $50.48B). The key difference: Realty Income Corp is far larger — about 27.9× Mesoblast Limited's market cap, and Realty Income Corp pays a 6.11% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Realty Income Corp for 127 Days on average.
| MESO | O | |
|---|---|---|
Market Cap | $1.81B | $50.48B |
Volume | 240,620 | 6,493,749 |
Sector | Health | Real Estate |
52-Week High | $20.96 | $67.56 |
52-Week Low | $13.19 | $53.35 |
Typical Hold Time | 14 Days | 127 Days |
Enterprise Value | $1.89B | $81.11B |
Dividend Yield | — | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Realty Income (O) trades at $54.17, down 0.15% with a bearish technical signal. The stock faces pressure from rising Treasury yields but maintains strong fundamentals including 92.56% gross margins and consistent dividend payments. Recent earnings have missed expectations, though revenue growth continues with 2025 reaching $5.75B. Analyst consensus remains positive with a $64.80 price target despite technical weakness.
The stock offers income potential with its 6%+ dividend yield and 136 consecutive dividend increases, but faces headwinds from interest rate sensitivity and recent earnings misses. Long-term fundamentals remain solid with A-rated credit and near-99% occupancy, though near-term technical pressure suggests cautious entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
